Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …

Gastrointestinal (GI) cancer constitutes a highly lethal entity among malignancies in the last
decades and is still a major challenge for cancer therapeutic options. Despite the current …

Abstract Background Biliary tract cancers (BTCs) comprise a heterogeneous group of
aggressive malignancies with unfavorable prognoses. The benefit of chemotherapy seems …

Objective We sought to identify patients at risk of “futile” surgery for intrahepatic
cholangiocarcinoma using an artificial intelligence (AI)–based model based on preoperative …

Background: Systemic inflammation is relevant in intrahepatic cholangiocarcinoma (iCCA),
but controversial results exist on the prognostic role of inflammatory indexes and their …

Background Unresectable intrahepatic cholangiocarcinoma (iCCA) has a poor prognosis
despite treatment with standard combination chemotherapy. We aimed to evaluate the …

Purpose Dedicated gene signatures in small (SD-iCCA) and large (LD-iCCA) duct type
intrahepatic cholangiocarcinoma remain unknown. We performed immune profiling in SD …

Cholangiocarcinoma is the second most common primary liver cancer, and its global
incidence has increased in recent years. Radical surgical resection and systemic …

Liver cancer is a leading cause of cancer-related deaths worldwide, highlighting the need
for innovative approaches to understand its complex biology and develop effective …

This study aims to determine the predictive role of dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) derived radiomic model in tumor immune profiling and …